---
name: target-profile
description: | Use when this capability is needed.
metadata:
  author: huifer
---

# Target Profile Skill

Generate comprehensive target dossiers for drug discovery decision-making.

## Quick Start

```
/target EGFR
/target-profile KRAS G12C
Create a target dossier for HER2 including clinical trials
Analyze druggability of BRAF V600E
```

## What's Included

| Section | Description | Data Source |
|---------|-------------|-------------|
| **Executive Summary** | Key insights in one page | Aggregated |
| **Target Overview** | Gene/protein name, class, location | UniProt |
| **Druggability** | Tractability scores, target class | Open Targets |
| **Disease Associations** | Associated diseases, evidence scores | Open Targets |
| **Pathways** | Signaling pathways, interactions | KEGG, Reactome |
| **Competition** | Existing drugs, pipeline | ChEMBL, DrugBank |
| **Safety** | Known safety concerns | Pharos, SIDER |

## Data Sources

| Source | API | Coverage |
|--------|-----|----------|
| Open Targets | `api.opentargets.org` | 20k+ targets, 1.2M associations |
| UniProt | `rest.uniprot.org` | 200M+ proteins |
| ChEMBL | `www.ebi.ac.uk/chembl/api` | 2.5M+ compounds |
| KEGG | `rest.kegg.jp` | 500+ pathways |
| Reactome | `reactome.org` | 2600+ pathways |

## Output Structure

```markdown
# EGFR Target Profile

## Executive Summary
EGFR is a high-tractability receptor tyrosine kinase with strong validation
in NSCLC. 9 drugs approved, 34 in development. Key opportunity: resistance
mechanisms and combination therapies.

## Quick Stats
| Metric | Value |
|--------|-------|
| Tractability | 8.2/10 (Small molecule) |
| Disease Associations | 142 diseases |
| Approved Drugs | 9 |
| Pipeline Candidates | 34 |
| Safety Tier | 2 (Moderate risk) |

## 1. Target Overview
- **Gene**: EGFR (ERBB1)
- **Protein**: Epidermal growth factor receptor
- **Class**: Receptor tyrosine kinase
- **Location**: Cell membrane (Plasma membrane)
- **Length**: 1210 amino acids
- **MW**: 134 kDa

## 2. Druggability Assessment
### Tractability Scores
| Modality | Score | Evidence |
|----------|-------|----------|
| Small molecule | 8.2/10 | 9 approved drugs |
| Antibody | 7.8/10 | 4 approved antibodies |
| PROTAC | 6.5/10 | Emerging approach |

### Target Development Level
**Tclin (Highest)** - Target with drugs approved for clinical use

## 3. Disease Associations
| Disease | Association Score | Evidence Type |
|---------|------------------|---------------|
| Lung adenocarcinoma | 0.95 | Genetic association |
| Glioblastoma | 0.87 | Somatic mutation |
| Head and neck cancer | 0.82 | Genetic association |

## 4. Pathway Context
- **Primary Pathway**: ErbB signaling pathway (KEGG: hsa04012)
- **Upstream**: EGF, TGF-alpha, Amphiregulin
- **Downstream**: MAPK, PI3K-Akt, JAK-STAT
- **Cross-talk**: MET, HER2, HER3

## 5. Competitive Landscape
### Approved Drugs
| Drug | Company | Year | Type | Indication |
|------|---------|------|------|------------|
| Erlotinib | Astellas | 2004 | TKI | NSCLC |
| Gefitinib | AstraZeneca | 2003 | TKI | NSCLC |
| Osimertinib | AstraZeneca | 2015 | 3rd-gen TKI | NSCLC |

### Pipeline (Selected)
| Drug | Company | Phase | Differentiation |
|------|---------|-------|----------------|
| Lazertinib | Yuhan | III | 3rd-gen, wild-type sparing |
| Nazartinib | Novartis | III | 3rd-gen, CNS active |

## 6. Safety Considerations
- **On-target toxicity**: Skin rash, diarrhea (class effect)
- **Off-target concerns**: Cardiac toxicity (rare)
- **Safety Tier**: 2 (Manageable risk)

## 7. Key Opportunities
1. Resistance mechanisms (C797S, MET amplification)
2. Combination therapies (EGFR + MET)
3. CNS-penetrant candidates
4. Biomarker-driven patient selection

## 8. Key Risks
1. Crowded competitive space
2. Generic competition (1st gen)
3. Resistance development
```

## Examples

### Basic Profile
```
/target EGFR
```

### With Specific Focus
```
/target KRAS --focus safety
Analyze safety profile of BTK
/target HER2 --focus competition
```

### Compare Multiple Targets
```
Compare targets EGFR, HER2, HER3 for NSCLC treatment
Rank KRAS, NRAS, HRAS by druggability
```

### Specific Analysis
```
/target BRAF V600C
Assess druggability of mutant BRAF
What is the tractability of KRAS G12C?
```

## Running Scripts

The `scripts/` directory contains data fetching utilities:

```bash
# Fetch basic target data
python scripts/fetch_target_data.py EGFR --output data.json

# Include all sources
python scripts/fetch_target_data.py EGFR --uniprot --chembl --pathways -o full.json

# Specific data only
python scripts/fetch_target_data.py KRAS --diseases-only
```

## Requirements

None for basic use (uses public APIs).

For advanced features and scripts:
```bash
pip install requests pandas
```

## Additional Resources

- [Open Targets API Reference](reference/opentargets-api.md)
- [Data Schema Definition](reference/data-schema.md)
- [Fetch Script Usage](reference/fetch-script.md)

## Best Practices

1. **Use official gene symbols** (HGNC nomenclature) for best results
2. **Include mutation** if relevant (e.g., "KRAS G12C")
3. **Specify focus** when you need deeper analysis on one area
4. **Compare targets** to support decision-making

## Common Pitfalls

| Pitfall | Solution |
|---------|----------|
| Ambiguous gene names | Use official HGNC symbols |
| Multiple isoforms | Specify isoform number if needed |
| Species confusion | Assume human unless specified |
| Outdated info | Data is current as of last API fetch |

---
> Converted and distributed by [TomeVault](https://tomevault.io/claim/huifer) — claim your Tome and manage your conversions.
<!-- tomevault:4.0:skill_md:2026-04-13 -->
